Fiera Capital Corp Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Fiera Capital Corp

  • $31.6 Billion
  • Q3 2024

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 10, 2022
SELL
$83.14 - $145.99 $3.09 Million - $5.42 Million
-37,111 Closed
0 $0
Q1 2022

May 09, 2022
SELL
$110.08 - $142.92 $161,377 - $209,520
-1,466 Reduced 3.8%
37,111 $4.4 Million
Q4 2021

Feb 08, 2022
SELL
$99.73 - $148.48 $306,869 - $456,872
-3,077 Reduced 7.39%
38,577 $5.32 Million
Q3 2021

Nov 12, 2021
SELL
$98.85 - $138.91 $49,425 - $69,455
-500 Reduced 1.19%
41,654 $5.79 Million
Q2 2021

Aug 11, 2021
SELL
$65.78 - $105.02 $197,274 - $314,954
-2,999 Reduced 6.64%
42,154 $3.08 Million
Q1 2021

May 11, 2021
BUY
$64.07 - $91.75 $99,308 - $142,212
1,550 Added 3.55%
45,153 $3.09 Million
Q4 2020

Feb 09, 2021
SELL
$65.07 - $98.24 $44,182 - $66,704
-679 Reduced 1.53%
43,603 $3.74 Million
Q3 2020

Nov 12, 2020
SELL
$59.04 - $77.95 $74,036 - $97,749
-1,254 Reduced 2.75%
44,282 $2.88 Million
Q2 2020

Aug 07, 2020
SELL
$29.01 - $74.23 $49,549 - $126,784
-1,708 Reduced 3.62%
45,536 $3.33 Million
Q1 2020

May 08, 2020
SELL
$27.51 - $57.29 $48,362 - $100,715
-1,758 Reduced 3.59%
47,244 $1.61 Million
Q4 2019

Feb 06, 2020
SELL
$40.86 - $57.65 $45,150 - $63,703
-1,105 Reduced 2.21%
49,002 $2.67 Million
Q3 2019

Nov 12, 2019
BUY
$37.38 - $49.47 $1.87 Million - $2.48 Million
50,107 New
50,107 $2.09 Million

Others Institutions Holding BHVN

# of Institutions
11
Shares Held
792K
Call Options Held
0
Put Options Held
0
View Full List

About Biohaven Pharmaceutical Holding Co Ltd.

BHVN Quotes by TradingView
  • Ticker BHVN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,645,000
  • Market Cap $3.18B
  • Description
  • Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...
More about BHVN
Track This Portfolio

Track Fiera Capital Corp Portfolio

Follow Fiera Capital Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fiera Capital Corp, based on Form 13F filings with the SEC.

News

Stay updated on Fiera Capital Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email